United States securities and exchange commission logo June 24, 2024 Michael Breen Interim Chief Executive Officer GT Biopharma, Inc. 9350 Wilshire Blvd. Suite 203 Beverly Hills, CA 90212 Re: GT Biopharma, Inc. Registration Statement on Form S-1 Filed June 20, 2024 File No. 333-280326 Dear Michael Breen: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Roger W. Bivans, Esq.